Current Environment:

Summary

There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.

Conditions

Anesthesia, Neurotoxicity, Child Development

Recruitment Status

Recruiting

Eligibility Criteria

Inclusion Criteria:

Younger than 2 years (chronological age)
Scheduled for anaesthesia that is expected to last at least 2 hours (and/or total operating room time is scheduled to be at least 2.5 hours)
Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.

Exclusion Criteria:

Known neurologic, chromosomal or congenital anomaly which is likely to be associated with poor neurobehavioural outcome
Existing diagnosis of behavioural or neurodevelopmental disability
Prematurity (defined as < 36 weeks gestational age at birth)
Birth weight less than 2 kg.
Congenital cardiac disease requiring surgery
Intracranial neurosurgery and intracranial craniofacial surgery (isolated cleft lip is not an exclusion)
Previous cumulative exposure to general anaesthesia exceeding 2 hours
Planned future cumulative exposure to anaesthesia exceeding 2 hours before the age of 3 years.
Any specific contra-indication to any aspect of the protocol
Previous adverse reaction to any anaesthetic
Circumstances likely to make long term follow-up impossible
Living in a household where the primary language spoken at home is not a language in which we can administer the Wechsler Preschool and Primary School Intelligence Scale
Planned postoperative sedation with any agent except opioids (e.g. benzodiazepines, dexmedetomidine, ketamine, barbiturates, propofol, clonidine, chloral hydrate, and other non-opioid sedatives). For example if such sedation is planned for post-operative ventilation

Intervention

Intervention Type

Intervention Name

Drug

Sevoflurane

Drug

Remifentanil

Drug

Dexmedetomidine

Phase

Phase 3

Gender

All

Min Age

N/A

Max Age

2 Years

Download Date

March 2, 2022

Principal Investigator

N/A

Primary Contact Information

Andrew J Davidson, MD

+61393455233

andrew.davidson@rch.org.au

Suzette J Sheppard, Bsc (Hons)

+61393454901

suzette.sheppard@mcri.edu.au

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team: